The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
To understand Khavinson bioregulators you must first understand their origin — because the origin is inseparable from the evidentiary challenge. These compounds were not developed through the standard pharmaceutical pipeline. They were developed by one man, at one institution, over 40 years.
Vladimir Khavinson was born in 1946, educated at the Military Medical Academy in Leningrad, and spent the formative years of his career developing substances to enhance soldier resilience during the Cold War. His early insight — that organ-specific tissue extracts could restore function in aging or stressed organs — emerged from military biomedical research in the 1970s and 1980s. The compounds he developed were initially crude peptide extracts from animal organs, administered to Soviet military personnel and, later, to elderly patients in Russian clinical settings. The program was classified, opaque to Western science, and conducted under institutional conditions that have no direct Western equivalent.
The St. Petersburg Institute of Bioregulation and Gerontology, which Khavinson directed from its founding until his death in 2024, became the singular hub of this research program. Every aspect of the bioregulator pipeline — discovery, mechanism research, clinical trials, publication, patenting, commercialization — passed through or originated at the same institution. Khavinson published over 775 papers across more than four decades. He secured 196 patents. He authored foundational textbooks on peptide bioregulation. He introduced gerontology as a clinical specialty in Russia and served in international aging research organizations. The scale and consistency of his output is genuinely impressive. It is also the core evidentiary problem: the entire knowledge base for this compound class was built by one team with a financial and scientific stake in its conclusions.
THE CENTRAL TENSION
Khavinson bioregulators represent the most concentrated single-institution provenance of any compound class in this book. For most research chemicals covered here, the evidence is thin because there isn't much of it. For Khavinson bioregulators, the evidence is substantial in volume — 500+ publications, 6-to-8-year human longevity data, multiple clinical trials — but almost entirely from the institution that develops, manufactures, and sells the compounds. This is not unique in pharmaceutical history; many drugs were developed by their eventual manufacturers. The difference: Khavinson's program never left the institutional incubator and entered the independent pharmaceutical development pipeline where adversarial replication is built into the approval process. The compounds are used in Russia as registered medicines. In the West, they are research chemicals evaluated through a science that has not independently stress-tested the core claims. The 2025 Al-Dulaimi Epitalon replication at Brunel University is the first meaningful crack in the single-institution evidence wall. It is one study. For Epitalon. The other 13 compounds in this chapter await their own independent replications.
Khavinson died in 2024. His passing closed a chapter but did not end the program — the St. Petersburg Institute continues, and the community of practitioners and researchers working with his compounds has grown substantially in Western markets since approximately 2020. The commercialization of Khavinson bioregulators has accelerated most since his death, driven partly by the broader longevity medicine movement's hunger for novel mechanisms. The compounds now appear on dozens of research chemical vendor sites, in longevity protocols prescribed by functional medicine practitioners, and in community forums alongside compounds like Epitalon that have reached a wider audience through the anti-aging information ecosystem.
Khavinson's original clinical protocols for Cytomaxes (the crude extracts) used intramuscular injection at 10mg per dose, once daily for 10 consecutive days, administered 2-3 times per year. This protocol was derived from clinical practice in Russia using the registered Cytomaxes (Thymalin, Epithalamin) and represents the dosing in the landmark human longevity study. The 10-day intensive course structure reflects a bioregulatory philosophy: the goal is to trigger epigenetic resetting of gene expression patterns that then persist without continuous dosing, rather than achieving continuous drug exposure.
The community has adapted the Khavinson protocol for synthetic Cytogens, with several modifications: Dose: most community protocols use 2mg per injection rather than 10mg, reflecting the synthetic Cytogen's expected higher purity and potency per unit mass vs the crude Cytomax extract. Some protocols use 5mg. The 10mg original protocol dose is used by some practitioners prescribing Cytogen versions but the 2mg convention is more widely cited in community settings. Route: SubQ is increasingly preferred over IM by community users for convenience and reduced discomfort, though the original Khavinson protocol used IM. No pharmacokinetic comparison of SubQ vs IM for these compounds has been published. Duration: 10 consecutive days remains the standard course length, consistent with the original protocol. Frequency: 2 courses per year is standard; some protocols use 3 courses per year for more aggressive longevity approaches.
Parameter
Standard Community Protocol
Original Khavinson (Cytomaxes)
Notes
Dose per injection
2 mg (synthetic Cytogen)
10 mg (crude Cytomax)
Dose difference reflects purity/concentration, not necessarily potency equivalence
Route
SubQ (abdomen/thigh)
IM (intramuscular)
No PK comparison published; SubQ more convenient for self-administration
Duration per course
10 consecutive days
10 consecutive days
Consistent with original
Courses per year
2 (spring + autumn typical)
2-3
Spring/autumn timing is community convention, not clinically validated
Number of compounds
1-3 simultaneously (organ-targeted)
1-2 Cytomaxes
Community stacks are more complex than original protocols
Storage
2-8°C lyophilised; reconstitute with BAC water; use within 28 days
Refrigerated; clinical pharmacy dispensed
Standard peptide storage applies
ORGAN-TARGETED STACKING — THE COMMUNITY APPROACH
A common community practice is selecting multiple Khavinson Cytogens targeted to the organ systems of most concern to the individual — stacking them simultaneously during the 10-day course. Example protocols: Anti-aging comprehensive (Epitalon + Pinealon + Vilon + Vesugen): pineal/telomere + brain + immune + vascular. Cardiovascular focus (Cardiogen + Vesugen + Livagen): heart + vessel walls + cardiovascular/lymphocyte. Metabolic focus (Pancragen + Livagen + Vesugen): pancreas + liver/cardiovascular + vascular. Male longevity (Epitalon + Testagen + Cardiogen + Vesugen): telomere + reproductive + cardiac + vascular. The organ-targeted logic is intuitively appealing but has no clinical trial basis in Western medicine. The Khavinson original clinical programs used 1-2 compounds. The multi-compound stacking approach is extrapolated from the organ-specificity hypothesis.
The mechanism proposed for Khavinson bioregulators is both the most scientifically interesting and the most contested aspect of the class. If it is correct, it represents a completely novel route to gene expression modulation. If it is overstated, it is a plausible but unproven hypothesis dressed as established pharmacology.
Most bioactive peptides work through receptor-mediated signaling: a ligand binds a cell surface receptor, activates a second messenger cascade, and gene expression changes downstream. This is the familiar pharmacological story. Khavinson's bioregulators propose something fundamentally different: the short peptide sequences (2-4 amino acids) are small enough to penetrate cell nuclei. Once in the nucleus, they interact directly with chromatin — binding specific DNA sequences in promoter regions through steric and electrostatic complementarity. This direct DNA binding modifies histone acetylation and methylation patterns around those promoter regions, changing the accessibility of regulatory sequences to transcription factors. The result: gene expression is modulated without second messenger systems, without receptor engagement, through direct epigenetic reprogramming of transcriptional accessibility.
The critical aspect of the chromatin interaction model is sequence specificity: the argument that a two or four amino acid peptide has meaningful sequence-specific affinity for particular DNA promoter regions in the target organ. A tetrapeptide has 4 amino acids. DNA has 4 nucleotide bases. The combinatorial specificity available from a tetrapeptide binding a short DNA sequence could theoretically be organ-specific if the target sequences are sufficiently unique. Khavinson's group published computational and biochemical studies supporting this hypothesis. Livagen (Lys-Glu-Asp-Ala) has been specifically studied as a tool peptide for investigating nucleosome interaction and chromatin remodeling in hepatic tissue, providing some of the mechanistic cell biology support for the class. The weakness of the argument: four amino acids provide limited combinatorial specificity; whether the selectivity claimed in computational models translates to meaningful tissue-selectivity in a living organism with diverse chromatin environments requires substantially more independent evidence than currently exists.
The direct chromatin interaction mechanism is theoretically plausible. Short peptides capable of binding DNA or histones are known in biochemistry — the concept is not invented. Whether Khavinson's specific sequences achieve the selectivity and functional consequences claimed is the unresolved question. The 2025 Al-Dulaimi replication of Epitalon's telomere effect is the most significant independent validation — it confirms that Epitalon (AEDG tetrapeptide) produces telomere elongation in human cell lines via what appears to be telomerase upregulation or ALT (alternative lengthening of telomeres) activity. It does not directly confirm the chromatin interaction mechanism, but it independently confirms a cellular endpoint consistent with that mechanism. For the other 13 compounds in this chapter, the mechanistic data is substantially from Khavinson's own laboratory.
THE CYTOMAX vs CYTOGEN PROBLEM — WHY IT MATTERS FOR EVIDENCE
Cytomaxes are crude multi-component polypeptide extracts from animal organs. Thymalin comes from bovine thymus; Epithalamin from bovine pineal gland. They contain many peptides, not just the short sequences. Cytogens are the synthetic single-sequence versions — Vilon (Lys-Glu) is the active dipeptide isolated from Thymalin; Epitalon (Ala-Glu-Asp-Gly) is the active tetrapeptide isolated from Epithalamin. The 6-to-8-year human longevity study (n=266) used Thymalin and Epithalamin — the crude Cytomaxes, not the synthetic Cytogens. Community users buy and inject the synthetic Cytogens. The pharmacological properties of a crude multi-component organ extract are not identical to a single synthetic short peptide even if that peptide was 'isolated' from the extract. The evidence transfer from Cytomax trials to Cytogen use is assumed, not proven. This is the most important evidentiary gap in the practical use of Khavinson bioregulators.
Khavinson & Morozov (2003, Neuroendocrinology Letters, PMID 14523363). n=266 elderly and older persons at the St. Petersburg Institute + Institute of Gerontology in Kiev. 6-8 years of follow-up. Thymalin and Epithalamin (crude Cytomaxes) administered IM 10mg daily x 10 days per course, repeated for first 2-3 years of observation. Comparator: standard geriatric care. Results: normalization of cardiovascular, endocrine, immune, and nervous system indices. Significantly reduced mortality vs comparator group. This is the most frequently cited human longevity data for the bioregulator class and the study that undergirds the 'peptides of pineal gland and thymus prolong human life' claim in the paper's title. Evidence grade: C — it is a prospective clinical program, not a randomized controlled trial; non-blinded; single institution; conducted by the developing group; comparator group is not matched by randomization; the methodology does not conform to modern RCT standards required for drug approval in any Western jurisdiction. The findings are meaningful as clinical program data and are the strongest available human evidence. They are not proof by the standards of modern evidence-based medicine.
Multiple Khavinson Institute studies in rodent models (SHR mice, Wistar rats) show lifespan extension with Epithalamin and various Cytomaxes. Anisimov et al. (Biogerontology, 2003) reported Epitalon extended lifespan and reduced spontaneous tumor incidence in SHR mice. Additional studies report 15-24% mean lifespan extensions in treated vs control rodents across multiple strain models. Grade C: animal data from the developing institution; limited independent replication in animal models; the rodent-to-human translation of lifespan findings is always uncertain.
Epitalon (AEDG, Ala-Glu-Asp-Gly) — the Cytogen version of Epithalamin — has the most independently validated mechanism of any compound in the Khavinson class. Khavinson et al. (2004) reported human fibroblasts treated with Epitalon exceeded the Hayflick limit and completed additional cell divisions beyond normal senescence thresholds. Al-Dulaimi et al. (2025, Biogerontology, Brunel University London): independent replication confirming telomere elongation via telomerase upregulation or ALT activity in human cell lines. This is the first and only independent Western replication of a Khavinson bioregulator mechanism. It upgrades Epitalon's telomere evidence from Grade C (single lab) to Grade B (independent replication). Note: Epitalon has its own dedicated chapter elsewhere in this book with full detail.
Compound
Sequence
Target Organ
Best Available Evidence
Vilon
Lys-Glu (dipeptide)
Immune / thymus
T-cell differentiation, NK cell activity, reduced IL-1β/TNF-α in aged models. Human: included in Thymalin Cytomax trial data but not tested separately as isolated Cytogen in large human trial.
C — animal + Cytomax extrapolation
Livagen
Lys-Glu-Asp-Ala (tetrapeptide)
Cardiovascular / lymphocytes
Chromatin remodeling cell biology; heterochromatin decondensation in senescent cells; hepatic tissue gene expression. Most mechanistically studied bioregulator after Epitalon.
C — mechanistic cell biology
Cartalax
Ala-Glu-Asp-Pro (tetrapeptide)
Cartilage / connective tissue
Chondrocyte proliferation in tissue models; proposed effects on cartilage metabolic markers.
C — animal/cell culture
Pinealon
Glu-Asp-Arg (tripeptide)
Brain / pineal gland
Neuroprotective in rat cerebral ischemia-reperfusion model (Grigoriev 2012). Oxidative stress reduction in cell culture; BDNF pathway support.
C — animal replicated
Cortagen
Ala-Glu-Asp-Leu (tetrapeptide)
Cerebral cortex / peripheral NS
Cortical neuron protection in animal models; peripheral nervous system function support.
C — animal
Bronchogen
Ala-Glu-Asp-Leu (tetrapeptide)
Bronchial / pulmonary
Respiratory epithelial cell gene regulation; pulmonary tissue protection models.
C — animal/cell culture
Testagen
Lys-Glu-Asp-Gly (tetrapeptide)
Testes / male reproductive
Spermatogenesis support; testicular tissue gene expression.
C — animal
Cardiogen
Ala-Glu-Asp-Arg (tetrapeptide)
Heart / myocardium
Myocardial cell gene regulation; cardiac tissue protection models.
C — animal/cell culture
Chonluten
Lys-Glu-Asp (tripeptide)
Mucous membranes / gut / lung
GI and respiratory epithelial regulation; proposed tight junction support.
C — animal/cell culture
Crystagen
Lys-Glu-Asp-Pro (tetrapeptide)
Crystalline lens / eye
Lens epithelial cell protection; cataract prevention models.
C — animal/cell culture
Ovagen
Glu-Asp-Leu (tripeptide)
Ovaries / female reproductive
Oocyte function; ovarian tissue gene expression.
C — animal
Pancragen
Lys-Glu-Asp-Ala (tetrapeptide)
Pancreas
Pancreatic exocrine/endocrine gene regulation; insulin secretion support.
C — animal/cell culture
Prostamax
Lys-Glu-Asp-Gln (tetrapeptide)
Prostate
Prostate tissue gene regulation.
C — animal/cell culture
Vesugen
Lys-Glu-Asp (tripeptide)
Vascular endothelium
Endothelial gene regulation; angiogenesis support; atherosclerosis protection models.
C — animal/cell culture
Each of the 14 Khavinson Cytogens is profiled below with its sequence, target organ, mechanism claim, published evidence summary, and community use context. All operate under the same single-lab provenance framework described in Sections 1-3.
Vilon is the dipeptide Lys-Glu, the minimal active sequence isolated from Thymalin (the Cytomax thymic extract). At just two amino acids, it is the simplest compound in the Khavinson class and has among the highest theoretical oral bioavailability of any bioregulator — very short peptides have documented resistance to GI proteolysis in some contexts. Proposed mechanism: T-cell differentiation via thymic-derived signaling; reduction of pro-inflammatory cytokines (IL-1β, TNF-α) in aged immune cells; NK cell activity support. The immune senescence context: thymic involution begins in the 20s and accelerates through middle age; by age 60-70 the thymus is largely replaced by adipose tissue and T-cell output is severely reduced. Vilon's proposed role is restoration of thymic-like signaling without requiring thymic tissue. Community use: SubQ or IM injection; 2mg daily x 10 days, twice per year; also used in oral capsule form (some community data suggests partial activity at 2-5mg oral). Often stacked with Epitalon in standard Khavinson anti-aging protocols.
Livagen (Lys-Glu-Asp-Ala, tetrapeptide) has a somewhat unusual evidence profile within the Khavinson class: it has been used extensively as a research tool peptide in cell biology experiments specifically investigating chromatin remodeling and nucleosome interaction. This gives Livagen somewhat stronger mechanistic data than most other bioregulators — it has been the subject of studies examining how short peptides interact with heterochromatin in senescent lymphocytes, specifically its ability to decondense heterochromatin and make previously silenced gene regions accessible to transcription again. The cardiovascular target: restoration of gene expression in aged vascular and lymphocyte tissue. Community use: typically 2mg SubQ or IM daily x 10 days; used as part of cardiovascular-focused longevity protocols; often combined with Vesugen (the vascular Cytogen) and Cardiogen.
Cartalax targets cartilage and connective tissue and is used in protocols for joint health, osteoarthritis prevention, and connective tissue restoration in athletes. The proposed mechanism is stimulation of chondrocyte proliferation and regulation of cartilage-specific gene expression. Published data: in vitro chondrocyte proliferation studies; proposed effects on cartilage metabolic markers. Community use: SubQ or IM, 2mg daily x 10 days; 2-3 cycles per year; often stacked with BPC-157 or TB-500 for injury recovery protocols. The connective tissue indication is one of the more intuitively appealing applications — joint and cartilage decline is a near-universal feature of biological aging — and community uptake for this application is substantial.
Pinealon is the tripeptide Glu-Asp-Arg targeting the brain and pineal gland. It is the brain-specific Cytogen in the Khavinson series, distinct from Epitalon (which also targets the pineal gland via the telomere mechanism). Pinealon's proposed effects focus on neuroprotection, cognitive function, circadian rhythm support, and possibly BDNF pathway upregulation. The most cited preclinical data: Grigoriev et al. (2012, Advances in Gerontology) rat cerebral ischemia-reperfusion injury model showing neuroprotective effects consistent with the chromatin-interaction mechanism. Community use: increasing rapidly in the nootropic community alongside Epitalon. Typical protocol: 2mg SubQ or IM daily x 10 days, 2-3 times per year; often combined with Epitalon and N-Acetyl Semax Amidate for a cognitive longevity stack. The brain-specific targeting makes it conceptually attractive for cognitive aging concerns.
Cortagen targets the cerebral cortex and peripheral nervous system. It is the most neurologically focused bioregulator outside of Pinealon, with proposed effects on cortical neuron protection and peripheral nerve function preservation. The evidence base is primarily from Khavinson Institute animal studies examining cortical protection under stress conditions and peripheral nervous system function in aged animal models. Community use is less established than Pinealon, but it appears in protocols targeting neurodegeneration prevention and peripheral neuropathy. Typical protocol mirrors other bioregulators: 2mg SubQ or IM daily x 10 days, 1-2 cycles per year.
Bronchogen targets respiratory epithelium and pulmonary tissue. Noteworthy: its amino acid sequence (Ala-Glu-Asp-Leu) is identical to Cortagen (Ala-Glu-Asp-Leu). This reflects the Khavinson framework's emphasis on tissue context rather than unique sequences for each organ — the same short sequence may have different dominant effects depending on the tissue microenvironment into which it is administered and the pattern of promoter regions most relevant in that tissue. Proposed effects: respiratory epithelial gene regulation; pulmonary cell function preservation; protection against oxidative stress in lung tissue. Community use: primarily in protocols for respiratory health maintenance, post-inflammatory lung repair, and longevity stacks with respiratory components.
Testagen (Lys-Glu-Asp-Gly) targets male reproductive tissue and is used in protocols for supporting spermatogenesis, testicular function, and age-related reproductive decline. The proposed mechanism involves testicular gene expression regulation supporting Sertoli cell and Leydig cell function. Important context: Testagen is not a testosterone booster in the conventional sense — it does not act on the HPTA axis as a GnRH or LH mimetic. It proposes to restore gene expression patterns in testicular tissue rather than stimulating the hormonal signaling cascade. Community use: appears in male reproductive health and fertility-support protocols; often combined with Kisspeptin-10 or gonadorelin in HPTA support contexts, though these target different mechanisms. Typical protocol: 2mg SubQ daily x 10 days, 2 cycles per year.
Cardiogen targets myocardial tissue. Proposed mechanism: regulation of cardiac muscle cell gene expression, myocardial protection against age-related functional decline, and cardioprotective gene expression restoration. The evidence base is primarily animal models of cardiac aging and myocardial stress. Community use: increasingly incorporated into cardiovascular-focused longevity protocols alongside other cardiometabolic compounds. Often stacked with Vesugen (vascular) and Livagen (cardiovascular/lymphocyte) as a comprehensive cardiovascular bioregulator cluster. Typical protocol: 2mg SubQ or IM daily x 10 days, 2 cycles per year.
Chonluten (Lys-Glu-Asp, tripeptide) targets mucous membranes of both the GI tract and respiratory system, giving it a dual application for gut and lung epithelial health. The proposed mechanism involves tight junction regulation and epithelial gene expression restoration, with some mechanistic overlap with BPC-157 (though through a completely different pathway). This dual GI/pulmonary targeting is unusual in the Khavinson series. Community use: appears in gut health optimization protocols alongside BPC-157 and KPV; used by people with both GI and respiratory concerns. Chonluten's short sequence (three amino acids) gives it reasonable prospects for oral partial activity.
Crystagen (Lys-Glu-Asp-Pro) targets the crystalline lens of the eye. Its proposed application — prevention of cataract formation and preservation of lens transparency — is one of the most niche in the Khavinson series. The proposed mechanism: regulation of lens epithelial cell gene expression, preventing the protein aggregation and oxidative damage that drives lens clouding. This application has generated interest in the longevity community because cataract development is essentially universal with aging and surgical intervention is the current only treatment. Whether a topically applied or injected short peptide can meaningfully reach lens tissue and produce the claimed gene-regulatory effects remains unproven in independent studies.
Ovagen (Glu-Asp-Leu, tripeptide) is the female reproductive Cytogen, targeting ovarian tissue and oocyte function. Proposed effects: restoration of gene expression patterns in ovarian tissue, support of oocyte quality in aged ovaries, and contribution to ovarian reserve maintenance. This application is of growing interest in the longevity community as awareness of ovarian aging as a driver of systemic aging increases. Community use: appears in female-focused longevity protocols; often combined with Epitalon and Testagen (for male partners) as couple longevity protocols. The evidence base for Ovagen's specific ovarian effects is primarily in vitro and animal data from the Khavinson Institute.
Pancragen (Lys-Glu-Asp-Ala) targets the pancreas. Proposed effects: restoration of pancreatic gene expression for both exocrine (digestive enzyme production) and endocrine (insulin/glucagon secretion) functions. The metabolic aging application is conceptually interesting — pancreatic beta cell function declines with aging and is the proximal cause of age-related glucose dysregulation even in non-diabetic individuals. Community use: appears in metabolic optimization protocols. Some interest as a complement to GLP-1 medications for the beta cell preservation angle, though this combination has not been studied. Typical protocol: 2mg SubQ daily x 10 days, 2 cycles per year.
Prostamax (Lys-Glu-Asp-Gln) targets the prostate gland. Proposed effects: restoration of prostate tissue gene expression, support of prostate health maintenance, and protection against age-related prostate dysfunction. Community use: appears in male longevity protocols targeting prostate health. Important caveat: any compound claiming to modulate prostate gene expression requires careful evaluation in the context of prostate cancer risk — if Prostamax genuinely activates gene expression in prostate tissue, whether this activation is beneficial or potentially problematic in the context of subclinical prostate cancer is unknown. No safety data exists for this specific concern.
Vesugen (Lys-Glu-Asp, tripeptide) targets the vascular endothelium and is proposed to support angiogenesis, endothelial cell gene expression, and protection against atherosclerotic vascular changes. The vascular endothelium application is one of the most broadly relevant in the Khavinson series — endothelial dysfunction is a universal feature of vascular aging and a contributor to cardiovascular disease, cognitive decline, and organ failure. Mechanistic plausibility: short peptides with positive charge characteristics (Lys present) can interact with negatively charged DNA and cellular membranes. Community use: one of the more popular Khavinson bioregulators in Western protocols; often combined with Cardiogen, Livagen, and cardiovascular compounds. Typical protocol: 2mg SubQ daily x 10 days, 2-3 cycles per year.
The safety profile of Khavinson bioregulators is generally considered favorable based on the available data — but the available data is limited, single-institution, and covers primarily the crude Cytomax extracts rather than the synthetic Cytogens in isolation.
The foundational safety argument: short peptides of 2-4 amino acids are degraded by ubiquitous proteases throughout the body within minutes to hours of administration. Unlike synthetic large molecules that may accumulate or have off-target receptor interactions, very short peptides are metabolized to their constituent amino acids — which are normal nutritional components. This biodegradation argument is mechanistically sound and provides the basis for an expected low acute toxicity profile. The Khavinson clinical program treated thousands of patients over four decades with the Cytomaxes without reporting significant adverse events in the published literature. No serious adverse effects have been attributed to the synthetic Cytogen versions in published safety data, though systematic long-term safety monitoring has not been conducted with modern pharmacovigilance standards.
Practical safety considerations for community use: no drug interactions have been documented (mechanistically, very short peptides interacting with chromatin rather than receptors have limited pharmacokinetic interaction potential); no HPTA effects are expected or documented; the compounds are not WADA prohibited. The primary safety uncertainties: (1) the long-term effects of repeated epigenetic modulation at the chromatin level — the mechanism proposed, if real, is a form of gene expression reprogramming; (2) the quality of research chemical Cytogen preparations varies significantly; endotoxin contamination (absent from pharmaceutical manufacturing) is the primary safety risk of injectable research chemicals; (3) the prostate-specific compounds (Prostamax) carry theoretical concerns about gene expression activation in the context of subclinical prostate pathology that have never been evaluated.
One legitimate concern: if the Cytomaxes and Cytogens genuinely modulate gene expression in organ-specific ways, the implications for oncology (cancer gene expression is, after all, abnormal gene expression) deserve more attention than the published literature provides. This concern is not unique to Khavinson bioregulators — it applies to any compound claiming epigenetic reprogramming effects — but it warrants noting in a safety section given the depth of the mechanism claim.
The 6-to-8-year study (n=266) showed reduced mortality in a clinical program using crude Cytomaxes (Thymalin + Epithalamin), compared to standard geriatric care, at a single institution run by the compound developers. It did not use randomization, blinding, or matched control selection. By the standards of modern evidence-based medicine, this is a promising observational signal — not proof. The same data submitted to any Western regulatory agency as a longevity claim would require independent replication in a properly controlled RCT before approval. That replication does not exist.
The synthetic Cytogen (e.g., Vilon = Lys-Glu) was isolated as the active sequence from the crude Cytomax (Thymalin = multi-component bovine thymus extract). The assumption is that the Cytogen captures all the pharmacological activity of the Cytomax. This is plausible but unproven. Multi-component extracts may have synergistic effects between peptides; the presence of multiple bioactive sequences may contribute to the biological response in ways that a single isolated sequence does not replicate. The Cytogen may be more or less effective than the Cytomax; the human longevity trial data from Cytomaxes cannot be directly applied to Cytogen dosing and outcomes.
The organ-specificity claim — that Pinealon specifically targets pineal/brain tissue while Cardiogen specifically targets myocardium — is based on the hypothesis that the short peptide sequences have promoter-specific affinity for genes preferentially expressed in those organ tissues. This is a computational and cell biology hypothesis, not a demonstrated whole-organism pharmacokinetic reality. When injected SubQ or IM, these peptides circulate systemically before being degraded. Whether they achieve meaningful concentrations specifically in their target organ tissue, rather than distributing throughout the body, has not been proven with pharmacokinetic biodistribution studies using the synthetic Cytogens.
Khavinson died in 2024 but the St. Petersburg Institute continues. Additionally, independent researchers (as demonstrated by the Al-Dulaimi 2025 Epitalon study) are beginning to examine these compounds outside Russia. The commercialization of Khavinson bioregulators has accelerated in Western markets since approximately 2020, which paradoxically increases the probability of independent replication as more researchers encounter the compounds and their mechanism claims.
Epitalon (AEDG, Ala-Glu-Asp-Gly) is the most well-known Khavinson Cytogen — it has its own full chapter in this book. The other 13 Cytogens in this cluster chapter are distinct compounds with different sequences, different organ targets, and substantially less published data than Epitalon. The evidence base, mechanism validation, and community adoption of the other 13 compounds is substantially weaker than Epitalon's. The success of Epitalon as the 'breakthrough' compound in Western markets has created a halo effect where the entire Khavinson class benefits from Epitalon's evidence base in community discourse — this is not pharmacologically justified.
Khavinson VKh, Morozov VG. (2003). Peptides of pineal gland and thymus prolong human life. Neuroendocrinology Letters. 24(3-4):233-240. PMID 14523363. [The landmark 6-to-8-year human clinical program; n=266 elderly; Thymalin + Epithalamin Cytomaxes; mortality reduction vs standard care; the most-cited longevity evidence for the bioregulator class.]
Al-Dulaimi A, et al. (2025). Epitalon extends telomere length via telomerase upregulation in human cell lines. Biogerontology. Brunel University London. [The first significant independent Western replication of any Khavinson bioregulator mechanism; confirms Epitalon's telomere elongation effect independently of the Khavinson Institution; upgrades Epitalon's telomere evidence to Grade B.]
Khavinson VKh et al. Livagen (Lys-Glu-Asp-Ala) chromatin remodeling and heterochromatin decondensation in senescent lymphocytes. Multiple publications in Bulletin of Experimental Biology and Medicine and Advances in Gerontology. [Livagen's cell biology work provides mechanistic support for the direct chromatin interaction hypothesis; the most extensively documented mechanistic data for any non-Epitalon Cytogen.]
Anisimov VN, Khavinson VKh, et al. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. [Rodent lifespan extension and reduced tumor incidence; Grade C (single institution); the foundational animal longevity data for the synthetic Cytogen.]
Grigoriev EI et al. (2012). Protective effects of Pinealon (Glu-Asp-Arg) in rat cerebral ischemia-reperfusion model. Advances in Gerontology. [The most-cited individual compound study for Pinealon; neuroprotection in ischemia-reperfusion; consistent with chromatin interaction mechanism; single institution; Grade C.]
The Khavinson bioregulators are simultaneously the most intriguing long-term longevity program in this book and the one requiring the most epistemic humility. They may be exactly what they are claimed to be — or they may be a 40-year demonstration of confirmation bias at institutional scale. We do not yet have enough independent data to confidently distinguish between these possibilities.
The honest summary: Vladimir Khavinson built a research program that is genuinely unprecedented in gerontology — 40 years, 500+ publications, multi-year human clinical programs, a consistent mechanistic framework. The proposed mechanism (direct chromatin interaction with organ-specific gene expression restoration) is theoretically plausible and partially supported by cell biology data for Livagen and Epitalon. The 6-to-8-year human longevity data is the most compelling long-term bioregulator safety and efficacy signal available anywhere. Epitalon's 2025 independent replication is a meaningful validation of the class's core biological premise. And yet: every significant clinical claim, every mechanistic paper, every safety observation was produced by or through one institution with a commercial stake in a positive outcome. The compounds are used in Russia as registered medicines. In the West they are research chemicals with Grade C evidence across the board, except Epitalon which has reached Grade B for its telomere mechanism.
For community users: the risk-benefit profile of Khavinson bioregulators is more favorable than most research chemicals in this book. Very short peptides with rapid proteolytic degradation have an inherently low acute toxicity profile. The proposed mechanism (epigenetic chromatin regulation) is not receptor-mediated, meaning the drug interaction profile is likely minimal. The 40-year clinical use record in Russia, whatever its methodological limitations, provides a large practical safety dataset. The uncertainty is not primarily safety — it is efficacy. Whether these compounds produce the organ-specific gene expression restoration claimed, in the doses used by the community, via the route administered, in the human organism rather than an in vitro cell line, remains the open question. Proceed with appropriate expectations: these are interesting longevity research tools with a unique mechanism and a provocative but methodologically imperfect evidence base.
— End of Khavinson Bioregulator Cluster Chapter —
THE PEPTIDE BIBLE | Khavinson Bioregulators | For Research & Educational Purposes Only
Khavinson bioregulators: ultra-short synthetic peptides (2-4 amino acids; Cytogens) derived from the active sequences of organ-specific crude polypeptide extracts (Cytomaxes). Developed by Vladimir Khavinson (1946-2024) at the St. Petersburg Institute of Bioregulation and Gerontology over 40+ years. 500+ publications; 196 patents; single-institution provenance is the defining evidentiary characteristic. MECHANISM: direct chromatin interaction (not receptor-mediated); short peptides penetrate cell nuclei; bind DNA promoter regions via steric/electrostatic complementarity; modify histone acetylation/DNA methylation; restore youthful gene expression patterns in target organ tissue. Theoretically plausible; partially supported by cell biology data (especially Livagen chromatin work and Epitalon telomere data); not independently replicated at scale for most compounds. CYTOMAX vs CYTOGEN: Cytomaxes = crude multi-component organ extracts (Thymalin, Epithalamin); Cytogens = synthetic single-sequence peptides (Vilon, Epitalon, etc.). Most human clinical data is from Cytomaxes; community uses Cytogens; pharmacological equivalence is assumed not proven. LANDMARK HUMAN STUDY: Khavinson & Morozov 2003 (PMID 14523363): n=266 elderly; 6-8 years; Thymalin + Epithalamin Cytomaxes; IM 10mg daily x 10 days x 2-3 years; normalized organ functions; reduced mortality vs standard geriatric care. Grade C: non-randomized, non-blinded, single institution, no independent replication. INDEPENDENT REPLICATION: Al-Dulaimi 2025 (Biogerontology, Brunel University): Epitalon telomere elongation confirmed independently. First independent Western replication of any Khavinson mechanism. Upgrades Epitalon telomere evidence to Grade B. THE 14 CYTOGENS: Vilon (Lys-Glu, immune/thymus), Livagen (Lys-Glu-Asp-Ala, cardiovascular/lymphocytes), Cartalax (Ala-Glu-Asp-Pro, cartilage), Pinealon (Glu-Asp-Arg, brain/pineal), Cortagen (Ala-Glu-Asp-Leu, cortex/peripheral NS), Bronchogen (Ala-Glu-Asp-Leu, bronchial — same sequence as Cortagen), Testagen (Lys-Glu-Asp-Gly, testes), Cardiogen (Ala-Glu-Asp-Arg, heart), Chonluten (Lys-Glu-Asp, mucous membranes/gut/lung), Crystagen (Lys-Glu-Asp-Pro, lens), Ovagen (Glu-Asp-Leu, ovaries), Pancragen (Lys-Glu-Asp-Ala, pancreas), Prostamax (Lys-Glu-Asp-Gln, prostate), Vesugen (Lys-Glu-Asp, vessels). COMMUNITY PROTOCOL: 2mg SubQ daily x 10 days; 2 cycles per year (spring/autumn); organ-targeted stacking of 2-4 Cytogens per course. SAFETY: favorable profile expected (very short peptides degraded to amino acids within hours; no receptor-mediated drug interactions); 40-year Russian clinical use without serious adverse event reports; endotoxin testing on COA essential for injectable Cytogens. EVIDENCE GRADE: C for all 14 compounds in this chapter (animal + Cytomax extrapolation; no independent RCT for any individual Cytogen). Epitalon (covered in its own chapter) = Grade B for telomere mechanism after 2025 Al-Dulaimi replication. WADA: not prohibited. NOT WADA banned.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.